Journal
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
Volume 31, Issue 2, Pages 241-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.iac.2011.02.007
Keywords
Subcutaneous immunotherapy; Systemic reactions; Anaphylaxis
Categories
Funding
- NCATS NIH HHS [UL1 TR000077] Funding Source: Medline
- NIAID NIH HHS [T32 AI060515] Funding Source: Medline
Ask authors/readers for more resources
Subcutaneous allergen immunotherapy (SCIT) has been practiced for 100 years. Many trials have established the efficacy of SCIT in reducing symptoms of both seasonal allergic rhinitis and asthma due to aeroallergens. However, clinical benefits of SCIT are tempered by risks of injection-related systemic reactions and life-threatening anaphylaxis. This article reviews data derived from retrospective surveys conducted to define the incidence, prevalence, and factors contributing to injection-related fatal anaphylactic and near-fatal systemic reactions, as well as recently initiated longitudinal surveillance studies of SCIT reactions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
